ClinicalTrials.gg
Active, not recruitingNCT05063162cosMOGUpdated Oct 27, 2026

A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Myelin Oligodendrocyte Glycoprotein (MOG) Antibody-associated Disease (MOGAD)

A Phase 3 interventional study of Rozanolixizumab and Placebo in Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD), sponsored by UCB Biopharma SRL. Active, not recruiting at 55 sites in 20 countries. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Updated Oct 9, 20262 sites added2 sites removedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
113
Allocation
Randomized
Ages
18 Years to 89 Years
Sex
All
01

Study summary

The purpose of the study is to evalute the efficacy, safety and tolerability of rozanolixizumab for treatment of adult participants with myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD).

02

Conditions studied

  • Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)

Keywords

  • MOG
  • MOGAD
  • Rozanolixizumab
  • Myelin oligodendrocyte glycoprotein
  • Myelin oligodendrocyte glycoprotein antibody-associated disease
03

In context

Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease

23 studies on the registry are indexed under Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease; 20 are open to participants now.

This study's enrollment of 113 is below the median of 126 across 11 interventional studies indexed under Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease.

Browse Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease studies →

Lead sponsor

UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 17 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be ≥18 to ≤89 years of age, at the time of signing the
  • Confirmed diagnosis of MOGAD consistent with published diagnostic criteria for MOGAD
  • Participant has history of relapsing MOGAD with at least 1 documented relapse over the last 12 months and a documented positive serum MOG Ab test using a cell-based assay (CBA) within 6 months prior to randomization
  • Participant must be clinically stable at the time of the Screening Visit and during the Screening Period

Exclusion criteria

Exclusion Criteria:

  • Participant has been diagnosed with a neurological disease (including multiple sclerosis (MS) and aquaporin-4 positive neuromyelitis optica spectrum disorder (NMOSD)), or a systemic autoimmune disease that in the opinion of the investigator can interfere with the safety of the participant
  • Participant has a active infection (including unresolved or not adequately treated infection) as assessed by the investigator, including participants with a serious infection within 6 weeks prior to the first dose of the medicinal product (IMP)
  • Participant has a current or medical history of primary immunodeficiency
  • Participant tests positive for aquaporin-4 antibodies at Screening
  • Participant has a serum total IgG level ≤ 5.5g/L
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
113 participants (actual)

Study arms

  • Experimental
    Rozanolixizumab Arm

    Participants randomized into this arm will receive rozanolixizumab at pre-specified timepoints.

    Drug: Rozanolixizumab

  • Placebo comparator
    Placebo Arm

    Participants randomized into this arm will receive placebo at pre-specified timepoints to maintain the blinding.

    Other: Placebo

Interventions

  • * Pharmaceutical form: Solution for infusion * Route of administration: subcutaneous infusion Participants will receive pre-specified doses of rozanolixizumab.

    Also known as: UCB7665

  • OtherPlacebo

    * Pharmaceutical form: Solution for infusion * Route of administration: subcutaneous infusion Participants will receive placebo.

    Also known as: PBO

06

What researchers measure

Primary outcomes

  1. For Part A: Time from randomization to first independently centrally adjudicated relapse (TTFR) during the DB Treatment Period

    The TTFR (days) will be defined as the interval between the date of randomization and the first date of the objective relapse. During the Double Blind (DB) Treatment Period (Part A); EDB/EWD = End of Double-Blind/Early Withdrawal Visit

    Time frame: Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks; in isolated cases this can be up to approximately 204 weeks)

  2. For Part B: Incidence of treatment-emergent adverse events (TEAEs) during OLE Treatment Period

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. Open-Label Extension (OLE) Treatment Period (Part B); EOS/EWD = End of Study/Early Withdrawal Visit.

    Time frame: OLE Treatment Period (OLE Week 1) to EOS/EWD Visit (up to OLE Week 52)

  3. For Part B: Incidence of treatment-emergent adverse events (TEAEs) leading to permanent withdrawal of investigational medicinal product (IMP) during OLE Treatment Period

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP. TEAEs leading to discontinuation of the study are reported.

    Time frame: OLE Treatment Period (OLE Week 1) to EOS/EWD Visit (up to OLE Week 52)

Secondary outcomes

  1. For Part A: Change from Baseline in Low-Contrast Monocular Visual Acuity (Worst Affected Eye) measured by low-contrast Landolt C Broken Rings Chart at the EDB/EWD Visit

    Visual acuity is a measurement of the capacity for visual discrimination of fine details. Visual acuity tests are used to determine the smallest characters that can be read on a standardized chart. The Landolt C Broken Ring Chart uses standardized incomplete rings or "C", which are positioned in any direction in the chart (up, down, left, right, and 45 degree positions in between). The participant has to be able to indicate where the break of the "C" is located, by describing the position or by giving gesture.

    Time frame: Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks; in isolated cases this can be up to approximately 204 weeks)

  2. For Part A: Disability as assessed by Expanded Disability Status Scale (EDSS) scores at the EDB/EWD Visit (with confirmation at 3 months)

    The EDSS is an ordinal clinical rating scale ranging from 0 (normal neurologic examination) to 10 (death) in half-point increments with half steps from 1.0 to 9.5. The higher the value the higher is the level of impairment and disability.

    Time frame: Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks; in isolated cases this can be up to approximately 204 weeks)

  3. For Part A: Number of MOGAD related inpatient hospitalizations during the DB Treatment Period

    The total number of MOGAD related hospitalizations from Baseline through EDB/EWD Visit.

    Time frame: Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks; in isolated cases this can be up to approximately 204 weeks)

  4. For Part A: Incidence of treatment-emergent adverse events (TEAEs) during the DB Treatment Period

    An adverse event (AE) is any untoward medical occurrence in a patient or clinical study participant, temporally associated with the use of investigational medicinal product (IMP), whether or not considered related to the IMP. NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of IMP.

    Time frame: Baseline (Week 1) to EDB/EWD Visit (until a confirmed relapse or up to approximately 132 weeks; in isolated cases this can be up to approximately 204 weeks)

  5. For Part B: Independently centrally adjudicated annualized relapse rate (ARR) during the DB and OLE Treatment Period

    An ARR will be calculated for each participant prior to randomization into the Double-Blind Treatment Period (based on available historical data), and 2 ARRs after randomization to study treatment: first for relapses occurring during the Double-Blind Treatment Period and the second for relapses occurring during the OLE Treatment Period. The relapse episodes for each participant will be recorded throughout the entire study.

    Time frame: Baseline (Week 1) to EOS/EWD Visit (up to OLE Week 52)

07

Study locations

55 sites
  • Mog001 50297
    Scottsdale, Arizona 85259-5452, United States
  • Mog001 50450
    Palo Alto, California 94304, United States
  • Mog001 50101
    Aurora, Colorado 80045, United States
  • Mog001 50553
    Washington D.C., District of Columbia 20057, United States
  • Mog001 50308
    Tampa, Florida 33612, United States
  • Mog001 50472
    Peoria, Illinois 61637, United States
  • Mog001 50552
    Baltimore, Maryland 21287, United States
  • Mog001 50243
    Boston, Massachusetts 02114-3117, United States
  • Mog001 50104
    Rochester, Minnesota 55905, United States
  • Mog001 50568
    San Antonio, Texas 78229, United States
  • Mog001 50473
    Salt Lake City, Utah 84112, United States
  • Mog001 30022
    Melbourne, Australia
  • Mog001 40185
    Ghent, Belgium
  • Mog001 60033
    Porto Alegre, Brazil
  • Mog001 40195
    Hradec Králové, Czechia
  • Mog001 40721
    Teplice, Czechia
  • Mog001 40170
    Strasbourg, France
  • Mog001 40140
    Göttingen, Germany
  • Mog001 40177
    Münster, Germany
  • Mog001 40850
    Athens, Greece
  • Mog001 40146
    Pavia, Italy
  • Mog001 40629
    Roma, Italy
  • Mog001 40646
    Verona, Italy
  • Mog001 20068
    Chiba, Japan
  • Mog001 20307
    Isehara, Japan
  • Mog001 20049
    Kitakyushu-shi, Japan
  • Mog001 20143
    Kodaira, Japan
  • Mog001 20223
    Koriyama-shi, Japan
  • Mog001 20224
    Sendai, Japan
  • Mog001 20227
    Sendai, Japan
  • Mog001 20070
    Shinjuku-ku, Japan
  • Mog001 20032
    Suita-shi, Japan
  • Mog001 50486
    Culiacán, Mexico
  • Mog001 50485
    Mexico City, Mexico
  • Mog001 40840
    Bydgoszcz, Poland
  • Mog001 40485
    Coimbra, Portugal
  • Mog001 40669
    Porto, Portugal
  • Mog001 20226
    Goyang-si, South Korea
  • Mog001 40267
    Barcelona, Spain
  • Mog001 40161
    Madrid, Spain
  • Mog001 40341
    Málaga, Spain
  • Mog001 40350
    Murcia, Spain
  • Mog001 40049
    Seville, Spain
  • Mog001 40663
    Huddinge, Sweden
  • Mog001 40723
    Basel, Switzerland
  • Mog001 40337
    Bern, Switzerland
  • Mog001 40630
    Zurich, Switzerland
  • Mog001 40550
    Istanbul, Turkey (Türkiye)
  • Mog001 40726
    Izmir, Turkey (Türkiye)
  • Mog001 40648
    Samsun, Turkey (Türkiye)
  • Mog001 40725
    Sancaktepe, Turkey (Türkiye)
  • Mog001 20319
    Kyiv, Ukraine
  • Mog001 20228
    Ternopil, Ukraine
  • Mog001 40661
    Liverpool, United Kingdom
  • Mog001 40163
    Oxford, United Kingdom
08

References and documents

Publications

  • Mader S, Kumpfel T, Meinl E. Pathomechanisms in demyelination and astrocytopathy: autoantibodies to AQP4, MOG, GFAP, GRP78 and beyond. Curr Opin Neurol. 2022 Jun 1;35(3):427-435. doi: 10.1097/WCO.0000000000001052. PubMed 35674086 ↗

Individual participant data

Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.

Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed.All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.

Data sharing details ↗ · www.vivli.org

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2022 (actual). Primary completion is estimated for May 2027, 63 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2021
First posted
Sep 30, 2021
StartActual
Feb 2, 2022
Primary completionEst.
May 6, 2027
CompletionEst.
Jul 1, 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 2 sites removed
Show 2 added (2 Japan)
  • Mog001 20049 · Kitakyushu-shi, Japan
  • Mog001 20032 · Suita-shi, Japan
Show 2 removed
  • Mog001 20049 · Kitakyushu, Japan
  • Mog001 20032 · Suita, Japan
Oct 9, 2026
Show all 2 updates
  1. Oct 9, 2026
    2 sites added, 2 sites removed
    Show 2 added (2 Japan)
    • Mog001 20049 · Kitakyushu-shi, Japan
    • Mog001 20032 · Suita-shi, Japan
    Show 2 removed
    • Mog001 20049 · Kitakyushu, Japan
    • Mog001 20032 · Suita, Japan
    + 1 other change: verification date
  2. Sep 25, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05063162
Lead sponsor
UCB Biopharma SRL
Responsible party
Sponsor
First posted
Sep 30, 2021
Start date
Feb 2, 2022
Primary completion
May 6, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

UCB Cares
study director · 001 844 599 2273

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rozanolixizumab

Start the discussion